title: Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.
abstract: Raltegravir is an FDA approved inhibitor directed against human immunodeficiency virus type 1 (HIV-1) integrase (IN). In this study, we investigated the mechanisms associated with multiple strand transfer inhibitors capable of inhibiting concerted integration by HIV-1 IN. The results show raltegravir, elvitegravir, MK-2048, RDS 1997, and RDS 2197 all appear to encompass a common inhibitory mechanism by modifying IN-viral DNA interactions. These structurally different inhibitors bind to and inactivate the synaptic complex, an intermediate in the concerted integration pathway in vitro. The inhibitors physically trap the synaptic complex, thereby preventing target DNA binding and thus concerted integration. The efficiency of a particular inhibitor to trap the synaptic complex observed on native agarose gels correlated with its potency for inhibiting the concerted integration reaction, defined by IC(50) values for each inhibitor. At low nanomolar concentrations (<50 nM), raltegravir displayed a time-dependent inhibition of concerted integration, a property associated with slow-binding inhibitors. Studies of raltegravir-resistant IN mutants N155H and Q148H without inhibitors demonstrated that their capacity to assemble the synaptic complex and promote concerted integration was similar to their reported virus replication capacities. The concerted integration activity of Q148H showed a higher cross-resistance to raltegravir than observed with N155H, providing evidence as to why the Q148H pathway with secondary mutations is the predominant pathway upon prolonged treatment. Notably, MK-2048 is equally potent against wild-type IN and raltegravir-resistant IN mutant N155H, suggesting this inhibitor may bind similarly within their drug-binding pockets.
authors.affiliation: Institute for Molecular Virology, Saint Louis University Health Sciences Center, 1100 South Grand Boulevard, Saint Louis, Missouri 63104, USA. pandeykk@slu.edu
authors.forename: Krishan K
authors.initials: KK
authors.lastname: Pandey
authors.forename: Sibes
authors.initials: S
authors.lastname: Bera
authors.forename: Ajaykumar C
authors.initials: AC
authors.lastname: Vora
authors.forename: Duane P
authors.initials: DP
authors.lastname: Grandgenett
mesh_terms: D004279:DNA, Viral / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D015497:HIV-1 / Q000235:genetics / Q000378:metabolism; D006801:Humans; D019429:Integrase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D019426:Integrases / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use; D009154:Mutation / Q000187:drug effects; D011760:Pyrrolidinones / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology; D000068898:Raltegravir Potassium; D014779:Virus Replication / Q000187:drug effects / Q000235:genetics
chemical_list: D004279:DNA, Viral; D019429:Integrase Inhibitors; D011760:Pyrrolidinones; D015363:Quinolones; D000068898:Raltegravir Potassium; C509700:elvitegravir; D019426:Integrases
references.citation: Biochemistry. 2008 Sep 9;47(36):9345-54
references.pmid: 18702518
references.citation: J Antimicrob Chemother. 2009 Nov;64(5):1087-90
references.pmid: 19717396
references.citation: J Med Chem. 2006 Mar 23;49(6):1939-45
references.pmid: 16539381
references.citation: J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):509-15
references.pmid: 17133211
references.citation: J Med Chem. 2008 Aug 14;51(15):4744-50
references.pmid: 18646746
references.citation: Curr Med Chem Anticancer Agents. 2005 Jul;5(4):421-9
references.pmid: 16101492
references.citation: Viruses. 2009 Dec;1(3):713-36
references.pmid: 21994566
references.citation: AIDS Rev. 2009 Jan-Mar;11(1):17-29
references.pmid: 19290031
references.citation: EMBO J. 2006 Mar 22;25(6):1295-304
references.pmid: 16482214
references.citation: J Biol Chem. 2008 Aug 29;283(35):23599-609
references.pmid: 18577511
references.citation: Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8
references.pmid: 18227187
references.citation: J Virol. 2008 Jan;82(2):764-74
references.pmid: 17977962
references.citation: Viruses. 2009 Dec;1(3):780-801
references.pmid: 21994569
references.citation: J Biol Chem. 2006 Jan 6;281(1):461-7
references.pmid: 16257967
references.citation: J Mol Recognit. 2009 Nov-Dec;22(6):480-94
references.pmid: 19623602
references.citation: Biochemistry. 2009 Feb 24;48(7):1644-53
references.pmid: 19178153
references.citation: J Biol Chem. 1999 Jun 11;274(24):17358-64
references.pmid: 10358097
references.citation: Antimicrob Agents Chemother. 2009 Oct;53(10):4522-4
references.pmid: 19667293
references.citation: N Engl J Med. 2008 Jul 24;359(4):355-65
references.pmid: 18650513
references.citation: Biochemistry. 2010 May 4;49(17):3715-22
references.pmid: 20334344
references.citation: Methods. 2009 Apr;47(4):277-82
references.pmid: 19286458
references.citation: PLoS Pathog. 2008 Mar 28;4(3):e1000046
references.pmid: 18369482
references.citation: Science. 2000 Jan 28;287(5453):646-50
references.pmid: 10649997
references.citation: J Virol. 2007 Apr;81(8):3969-79
references.pmid: 17267486
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3358-68
references.pmid: 18591263
references.citation: Drug Resist Updat. 2010 Aug-Oct;13(4-5):139-50
references.pmid: 20570551
references.citation: J Virol. 2008 Nov;82(21):10366-74
references.pmid: 18715920
references.citation: J Virol. 2009 Aug;83(15):7706-17
references.pmid: 19458008
references.citation: J Virol. 2005 Jul;79(13):8208-16
references.pmid: 15956566
references.citation: Nucleic Acids Res. 2005 Feb 17;33(3):977-86
references.pmid: 15718297
references.citation: J Virol. 2009 Nov;83(22):11440-6
references.pmid: 19759152
references.citation: Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11233-8
references.pmid: 15277684
references.citation: Lancet. 2009 Sep 5;374(9692):796-806
references.pmid: 19647866
references.citation: J Med Chem. 2008 Sep 25;51(18):5843-55
references.pmid: 18763751
references.citation: J Virol. 2007 Nov;81(22):12189-99
references.pmid: 17804497
references.citation: N Engl J Med. 2008 Jul 24;359(4):339-54
references.pmid: 18650512
references.citation: Nucleic Acids Res. 2009 Mar;37(4):1193-201
references.pmid: 19129221
references.citation: Nucleic Acids Res. 1999 May 15;27(10):2202-10
references.pmid: 10219094
references.citation: Methods. 2009 Apr;47(4):237-42
references.pmid: 19232539
references.citation: Nat Rev Drug Discov. 2005 Mar;4(3):236-48
references.pmid: 15729361
references.citation: J Med Chem. 2006 Mar 9;49(5):1506-8
references.pmid: 16509568
references.citation: Nature. 2010 Mar 11;464(7286):232-6
references.pmid: 20118915
references.citation: J Mol Biol. 2008 Jul 11;380(3):504-19
references.pmid: 18565342
references.citation: J Virol. 1993 May;67(5):2628-36
references.pmid: 8474165
references.citation: Retrovirology (Auckl). 2008 Nov 5;2:11-16
references.pmid: 19915684
references.citation: Antimicrob Agents Chemother. 2010 Jan;54(1):491-501
references.pmid: 19901095
references.citation: J Virol. 2004 Apr;78(7):3210-22
references.pmid: 15016842
references.citation: Biochemistry. 2008 Dec 23;47(51):13481-8
references.pmid: 18991395
references.citation: Methods. 2009 Apr;47(4):229-36
references.pmid: 19049878
references.citation: J Virol. 2002 Apr;76(7):3105-13
references.pmid: 11884535
references.citation: J Mol Biol. 2009 May 29;389(1):183-98
references.pmid: 19362096